302 related articles for article (PubMed ID: 31676465)
1. Abnormal C-reactive protein blood levels as a specific biomarker of major depression and non-remission under antidepressants in schizophrenia.
Fond G; Micoulaud-Franchi JA; Faugere M; Boyer L; Faget-Agius C; Lançon C; Richieri R; Cermolacce M
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Mar; 97():109800. PubMed ID: 31676465
[TBL] [Abstract][Full Text] [Related]
2. Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set.
Fond G; Godin O; Brunel L; Aouizerate B; Berna F; Bulzacka E; Capdevielle D; Chereau I; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Le Strat Y; Micoulaud-Franchi JA; Misdrahi D; Rey R; Richieri R; Passerieux C; Schandrin A; Schürhoff F; Tronche AM; Urbach M; Vidalhet P; Llorca PM; Leboyer M;
J Affect Disord; 2016 Feb; 191():209-15. PubMed ID: 26674214
[TBL] [Abstract][Full Text] [Related]
3. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort.
Fond G; Boyer L; Berna F; Godin O; Bulzacka E; Andrianarisoa M; Brunel L; Aouizerate B; Capdevielle D; Chereau I; Coulon N; D'Amato T; Dubertret C; Dubreucq J; Faget C; Leignier S; Lançon C; Mallet J; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Leboyer M; Schürhoff F; Llorca PM;
Br J Psychiatry; 2018 Aug; 213(2):464-470. PubMed ID: 29871707
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory DEpression Advances in Schizophrenia (IDEAS): A precision medicine approach of the national FACE-SZ cohort.
Fond G; Godin O; Schürhoff F; Berna F; Aouizerate B; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Dubreucq J; Faget C; Leignier S; Lançon C; Mallet J; Marulaz L; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Leboyer M; ; Boyer L; Llorca PM
J Affect Disord; 2019 Feb; 245():468-474. PubMed ID: 30428447
[TBL] [Abstract][Full Text] [Related]
5. Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.
Fond G; Resseguier N; Schürhoff F; Godin O; Andrianarisoa M; Brunel L; Bulzacka E; Aouizerate B; Berna F; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Dubreucq J; Faget C; Gabayet F; Lançon C; Llorca PM; Mallet J; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Boyer L; Leboyer M;
Eur Arch Psychiatry Clin Neurosci; 2018 Sep; 268(6):541-553. PubMed ID: 29127503
[TBL] [Abstract][Full Text] [Related]
6. Improving the treatment and remission of major depression in homeless people with severe mental illness: The multicentric French Housing First (FHF) program.
Fond G; Tinland A; Boucekine M; Girard V; Loubière S; Boyer L; Auquier P;
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Apr; 99():109877. PubMed ID: 31987919
[TBL] [Abstract][Full Text] [Related]
7. High C-reactive protein levels are associated with depressive symptoms in schizophrenia.
Faugere M; Micoulaud-Franchi JA; Faget-Agius C; Lançon C; Cermolacce M; Richieri R
J Affect Disord; 2018 Jan; 225():671-675. PubMed ID: 28917193
[TBL] [Abstract][Full Text] [Related]
8. Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia.
Fond G; Faugere M; Faget-Agius C; Cermolacce M; Richieri R; Boyer L; Lançon C
Eur Arch Psychiatry Clin Neurosci; 2019 Dec; 269(8):879-886. PubMed ID: 30078128
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study.
Jha MK; Minhajuddin A; Chin-Fatt C; Greer TL; Carmody TJ; Trivedi MH
J Psychiatr Res; 2019 Jun; 113():165-171. PubMed ID: 30959227
[TBL] [Abstract][Full Text] [Related]
11. Depressive symptoms and chronic peripheral inflammation are associated with impaired functional remission in schizophrenia independently of psychotic remission.
Fond G; Faugere M; Richieri R; Cermolacce M; Korchia T; Micoulaud-Franchi JA; Sunhary de Verville PL; Boyer L; Lançon C
J Affect Disord; 2021 Feb; 280(Pt A):267-271. PubMed ID: 33220563
[TBL] [Abstract][Full Text] [Related]
12. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Jha MK; Minhajuddin A; Gadad BS; Greer T; Grannemann B; Soyombo A; Mayes TL; Rush AJ; Trivedi MH
Psychoneuroendocrinology; 2017 Apr; 78():105-113. PubMed ID: 28187400
[TBL] [Abstract][Full Text] [Related]
13. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
De Berardis D; Fornaro M; Orsolini L; Iasevoli F; Tomasetti C; de Bartolomeis A; Serroni N; De Lauretis I; Girinelli G; Mazza M; Valchera A; Carano A; Vellante F; Matarazzo I; Perna G; Martinotti G; Di Giannantonio M
CNS Spectr; 2017 Aug; 22(4):342-347. PubMed ID: 27702411
[TBL] [Abstract][Full Text] [Related]
14. Baseline serum C-reactive protein levels may predict antidepressant treatment responses in patients with major depressive disorder.
Zhang J; Yue Y; Thapa A; Fang J; Zhao S; Shi W; Yang Z; Li Y; Yuan Y
J Affect Disord; 2019 May; 250():432-438. PubMed ID: 30878656
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT study
Carlier A; Berkhof JG; Rozing M; Bouckaert F; Sienaert P; Eikelenboom P; Veerhuis R; Vandenbulcke M; Berkhof J; Stek ML; Rhebergen D; Dols A; Exel EV
J Affect Disord; 2019 Sep; 256():509-516. PubMed ID: 31279250
[TBL] [Abstract][Full Text] [Related]
16. Prescription of potentially inappropriate psychotropic drugs in homeless people with schizophrenia and bipolar disorders. Results from the French Housing First (FHF) program.
Fond G; Tinland A; Boucekine M; Girard V; Loubière S; Auquier P; Boyer L;
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():84-89. PubMed ID: 30153497
[TBL] [Abstract][Full Text] [Related]
17. Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder.
Wysokiński A; Margulska A; Strzelecki D; Kłoszewska I
Nord J Psychiatry; 2015 Jul; 69(5):346-53. PubMed ID: 25495587
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications.
Fernandes BS; Steiner J; Bernstein HG; Dodd S; Pasco JA; Dean OM; Nardin P; Gonçalves CA; Berk M
Mol Psychiatry; 2016 Apr; 21(4):554-64. PubMed ID: 26169974
[TBL] [Abstract][Full Text] [Related]
19. Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.
Bulzacka E; Boyer L; Schürhoff F; Godin O; Berna F; Brunel L; Andrianarisoa M; Aouizerate B; Capdevielle D; Chéreau-Boudet I; Chesnoy-Servanin G; Danion JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Le Gloahec T; Llorca PM; Mallet J; Misdrahi D; Rey R; Richieri R; Passerieux C; Roux P; Yazbek H; Leboyer M; Fond G;
Schizophr Bull; 2016 Sep; 42(5):1290-302. PubMed ID: 27143795
[TBL] [Abstract][Full Text] [Related]
20. Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort.
Fond G; Sunhary de Verville PL; Richieri R; Etchecopar-Etchart D; Korchia T; Faugere M; Godin O; Schürhoff F; Berna F; Aouizerate B; Capdevielle D; Chereau I; Clauss-Kobayashi J; Coulon N; Dorey JM; Dubertret C; Dubreucq J; Mallet J; Misdrahi D; Passerieux C; Pignon B; Rey R; Urbach M; Leboyer M;
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110335. PubMed ID: 33933539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
